Takeda pharmaceuticals news
Takeda announced the reorganization of its commercial and R&D operations -- its first major organizational move since naming Christophe Weber as COO, effective last April, and president, effective last June.Takeda said the reorganization is designed to strengthen communication between its commercial and R&D divisions.
Takeda's commercial division will establish five regional business units, as well as two specialty business units for oncology and vaccines, by April 1, 2015. The five commercial units will be Japan Pharma, U.S., Europe-Canada, Emerging Markets and Japan Consumer Healthcare. Christophe Bianchi, EVP of Takeda's oncology-focused Millennium Pharmaceuticals Inc. subsidiary, will become president of the specialty oncology unit. ...